Gujarat Alkalies and Chemicals Ltd. Overview
GACL is a Government of Gujarat-promoted, multi-product chlor-alkali company and, on a consolidated basis with its 60%-owned subsidiary GACL-NALCO Alkalies & Chemicals Pvt Ltd (GNAL), the third-largest caustic soda producer in India with approximately 3,000 tonnes per day of capacity at Vadodara and Dahej (CARE, Aug 2026). Its strategic identity rests on integration: chlorine and hydrogen co-produced with caustic soda are captively converted into a basket of more than 36 products, from chloromethanes and hydrogen peroxide to phosphoric acid, poly aluminium chloride and chlorotoluene derivatives. The business remains structurally exposed to electrochemical-unit (ECU) price cycles and power costs, which account for roughly 30–34% of revenue. After two loss-making consolidated years (FY24, FY25), FY26 was near break-even, and Q1 FY27 delivered record revenue and margin expansion. The investment case turns on renewable-power substitution, value-added chlorine sinks, and the turnaround of GNAL.
What the company does
GACL makes caustic soda (sodium hydroxide) through brine electrolysis using membrane-cell technology. The process co-produces chlorine and hydrogen in fixed ratios. Caustic soda is sold as lye, flakes and prills to alumina, textiles, pulp and paper, soaps and detergents, rayon and chemical customers. Chlorine and hydrogen, which in India often have low or negative merchant value, are converted captively into derivatives: chloromethanes, hydrochloric acid, sodium hypochlorite, aluminium chloride, poly aluminium chloride, chlorinated paraffin, chlorotoluene derivatives (benzyl chloride, benzyl alcohol, benzaldehyde), and hydrogen peroxide. A separate potash line produces caustic potash and potassium carbonate. Phosphoric acid (including purified/food-grade) and hydrazine hydrate extend the portfolio into non-chlorine specialties.
Company's own description (FY26 Annual Report, paraphrased)
The company describes itself as a multi-product chemical manufacturer and one of India's leading producers of caustic soda lye, with vision language centred on being recognised as a dynamic, modern and eco-friendly chemical company with enduring ethics. Its mission statements emphasise responsible business conduct, continuous performance improvement through innovation, and the highest standards of ethics and product quality. Its letterhead tagline is "Promoting Green Technology".
Business and revenue model
Revenue model: ~100% product sales (manufactured chemicals). Minor service-like income arises from utility supply, infrastructure sharing and agency arrangements with GNAL (sale of chlorine, steam, power, DM water, nitrogen, etc.), and from hydrogen sold by pipeline (NOCIL contract from Feb 2026). No subscription or licensing income.
FY26 standalone composition: net external sales ₹4,246.50 Cr; other operating income ₹111.58 Cr; revenue from operations ₹4,358.07 Cr; other income ₹116.62 Cr (AR FY26).
Export share: exports of ~₹920 Cr in FY26 (~21% of revenue, derived) against imports of ~₹444 Cr, giving a natural FX hedge (CARE, Aug 2026).
Volume base: total production of all products 21,75,302 MT in FY26, up 3.03% from 21,11,229 MT (AR FY26).
Value-chain position
GACL sits in the upstream/intermediate tier of the inorganic chemicals chain. Inputs are salt (brine), electricity (its largest cost), natural gas, coal/biofuel for steam, potassium chloride, rock phosphate/phosphoric inputs and toluene. Outputs are commodity intermediates sold B2B. The company is integrated backward into power (90 MW gas-based captive plant, 171.45 MW wind, 36.42 MW solar, plus group-captive renewable SPVs) and forward into chlorine and hydrogen derivatives.
Customer types and end-markets
Per CARE (Aug 2026), products serve textiles, pulp and paper, alumina/aluminium, soaps and detergents, rayon, fertilisers, petroleum, pharmaceuticals, agrochemicals, water treatment, inks and paints. NALCO is a contracted offtaker of a prescribed quantity of GNAL caustic soda via tender-based work orders. The newly approved high-purity hydrogen peroxide plant targets semiconductor fabrication, solar-cell manufacturing and advanced electronics.
Independent characterisation
GACL is best understood as a cost-and-integration play on Indian chlor-alkali rather than a specialty chemicals company. Its earnings are dominated by the ECU spread (caustic + chlorine + hydrogen realisation minus power). The FY24–FY26 downturn exposed three structural pressures: a national capacity build-out (India 6.7 Mtpa by March 2026) outpacing demand, persistently negative chlorine realisations (₹7,000–8,000/MT in FY26), and heavy depreciation from a ₹2,000+ Cr capex wave (Dahej expansion, chlorotoluene, GNAL). Diversification is real but its contribution is not yet large enough to offset the caustic cycle.
Strategy
Stated strategic themes (FY26 AR, Q1 FY27 investor presentation, CARE PR — paraphrased)
-
Green Chemistry / renewable power substitution: raise renewable share of electricity from ~35% to ~60% in the medium term through group-captive hybrid wind-solar SPVs, short-term renewable procurement (NVVNL, Tata Power, Kreate Energy, PR Energy) and own solar.
-
Chlorine value maximisation: add captive chlorine sinks (two HCl synthesis units; chlorotoluene ramp-up; phosphoric acid using HCl) to escape negative merchant chlorine pricing.
-
Value-added and high-purity products: high-purity/E-grade hydrogen peroxide for semiconductor and solar supply chains; food-grade phosphoric acid; expansion of caustic flakes and caustic potash.
-
Cost leadership: membrane-cell efficiency, power-cost reduction (₹7.90/unit FY26 vs ₹8.42), replacement of steam generation with four biofuel/coal-fired boilers.
-
Infrastructure sharing with GNAL to avoid duplication and lift utilisation at Dahej.
-
Vision 2047: long-term strategy document approved by the Board on 23 Jul 2026 (content not publicly detailed in sources reviewed).
Initiative register (last 24 months)
| Date | Initiative | Investment | Status / intent |
|---|---|---|---|
| Nov–Dec 2024 | 62.7 MW hybrid RE with Aditya Birla Renewables (26% stake) | Equity share not disclosed | Under execution by SPV |
| 26 Mar 2025 | GIPCL 75 MW solar (group captive; 50% to GACL) | ₹45 Cr equity | Fully operative |
| 16 May 2025 | HCl synthesis unit #1 (90–120 MTPD) at Dahej | ₹35 Cr | Absorbs 80–100 TPD extra chlorine |
| Aug–Nov 2025 | 75.9 MW hybrid RE with CleanMax (26% stake) | ₹19.42 Cr (Nov 2025) + ₹32.33 Cr (Jun 2026) | Under execution; June 2026 partnership referenced 75.9 MW wind + 84.34 MWp solar |
| 2,025 | SPV with GMDC for 60 MW RE | — | Approved in principle |
| 14 Feb 2026 | Hydrogen pipeline to NOCIL | — | ~20,000 Nm3/day; ~₹9 Cr annual revenue; 5-year contract |
| 6 Feb 2026 | Governance: ESG committee merged into CSR committee | — | Completed |
| 29 May 2026 | 5,000 TPA high-purity H2O2 plant, Dahej | ₹67 Cr | 18 months from technology kick-off; ~₹42 Cr revenue potential; funded from internal accruals |
| 23 Jul 2026 | HCl synthesis unit #2, Dahej | ₹55 Cr | In-principle; HCl to feed phosphoric acid plant |
| 23 Jul 2026 | Vision 2047 document | — | Approved |
| FY27–FY29 | Capex programme: food-grade phosphoric acid (Dahej), four biofuel/coal boilers, flakes & potash expansion, E-grade H2O2, maintenance | ₹1,300–1,400 Cr; 60–70% debt-funded (GSFS/financial institutions) | Per CARE Aug 2026 |
| FY24–FY28 | Capacity expansion + renewable programme (Q1 FY27 presentation references ~₹315 Cr across FY24–FY28 for selected projects; context partly unclear in excerpt) | ~₹315 Cr | Not fully verified |
Medium-term financial targets / guidance
GACL does not publish formal numerical guidance. Implicit targets: renewable share ~60% (medium term); consolidated gearing ~0.40x maintained through capex (CARE expectation); CARE projects consolidated interest coverage improving above 4–5x and total debt/PBILDT below 3x in the near-to-medium term.
Sustainability commitments
Renewable-power scale-up (above); treated waste-water reuse via VJSPL (50 MLD STP, Vadodara); Q1 FY27-era commentary references a renewable share around 59% in some periods (ScanX) — this conflicts with CARE's ~35% FY26 figure; the difference likely reflects measurement basis (point-in-time vs annual, or a specific complex). Discrepancy flagged.
Products & Services
GACL states it has more than 36 products. Disclosed product-level capacity data is incomplete in the FY26 documents reviewed; capacities shown below are from company investor presentations where available and dated accordingly.
Chlor-alkali core
| Product | Description & key uses | Target customers | Capacity / status | Notes |
|---|---|---|---|---|
| Caustic soda lye | NaOH solution (typically ~48–50%), membrane-cell | Alumina, textiles, pulp & paper, soaps & detergents, chemicals | Group ~3,000 TPD (lye + flakes, consolidated with GNAL) at 31 Mar 2026 (CARE). Standalone lye capacity cited as 5,85,750 MT at 31 Mar 2025 (IIFL summary) | Flagship product; GACL third-largest producer in India |
| Caustic soda flakes | Solid NaOH, for distant/export markets | Exporters, detergent, textile, chemical buyers | Expansion of flaking facilities part of FY27–FY29 capex (CARE) | GNAL operates a flaking unit |
| Caustic soda prills | Bead-form NaOH | Specialty/export | — | — |
| Liquid chlorine | Co-product, sold in tonners/tankers or piped | Chemical, pharma, water treatment, PVC/EDC makers | — | Realisations negative (~₹7,000–8,000/MT) in FY26 (CARE) |
| Hydrochloric acid | From chlorine + hydrogen synthesis | Steel pickling, chemicals, captive phosphoric acid | New 90–120 MTPD unit (₹35 Cr, May 2025) plus second unit (₹55 Cr, Jul 2026) at Dahej | Key chlorine sink |
| Sodium hypochlorite | Bleach/disinfectant | Water treatment, textiles, municipal | — | — |
| Hydrogen (gas) | Co-product | NOCIL (pipeline, ~20,000 Nm3/day, ~₹9 Cr annual revenue, 5-year contract); captive H2O2 | Pipeline commissioned 14 Feb 2026 | Monetises surplus hydrogen |
Chlorine derivatives
| Product | Description & uses | Target customers | Capacity / status |
|---|---|---|---|
| Chloromethanes (methylene chloride, chloroform; carbon tetrachloride co-product) | Solvents and refrigerant/fluorochemical feedstock | Pharma, agrochemicals, fluorochemicals, foam | Plants at Vadodara and Dahej (Dahej plant adjacent to GNAL uses GNAL surplus power); capacity not disclosed in FY26 sources |
| Chlorotoluene derivatives: benzyl chloride, benzyl alcohol, benzaldehyde | Intermediates for pharma, flavours & fragrances, plasticisers, agrochemicals | Pharma, F&F, agro intermediates | 90 TPD project (~₹350 Cr) at Dahej; production started FY2024-25; ramp-up slower than expected (CARE 2026) |
| Aluminium chloride (anhydrous) | Friedel-Crafts catalyst | Dyes, pharma, agro intermediates | — |
| Poly aluminium chloride (various grades) | Coagulant | Municipal and industrial water treatment, paper | — |
| Chlorinated paraffin | Plasticiser / flame retardant | PVC compounding, lubricants | — |
| Sodium chlorate | Oxidant | Pulp bleaching (ClO2), chemicals | — |
| Stable bleaching powder / other chlorine products† | Disinfection | Water treatment | — |
Peroxide and hydrogen-based products
| Product | Description & uses | Target customers | Capacity / status |
|---|---|---|---|
| Hydrogen peroxide (standard grades) | Eco-friendly bleaching agent | Paper & pulp, textiles, chemicals | Combined capacity 54,120 MTPA (100% basis) per June 2022 presentation (Vadodara 13,860; Dahej 40,260) |
| High-purity / electronic-grade hydrogen peroxide | Ultra-pure grade | Semiconductor fabs, solar-cell makers, electronics | 5,000 TPA (100%) plant approved 29 May 2026; ₹67 Cr; 18 months from technology kick-off; ~₹42 Cr annual sales potential. CARE also references an "E-grade" H2O2 facility in the FY27–FY29 capex plan |
| Hydrazine hydrate | Reducing agent | Agrochemicals, pharma, blowing agents, water treatment | 10,000 TPA (80%) project approved FY2015-16; first lot dispatched FY2022-23† |
Potash, phosphate and other inorganics
| Product | Description & uses | Target customers | Capacity / status |
|---|---|---|---|
| Caustic potash lye & flakes | KOH | Fertiliser (potassic), soaps, batteries, chemicals | Initial capacity 16,500 MTPA (historic presentation); expansion part of FY27–FY29 capex (CARE) |
| Potassium carbonate (granules, powder) | Glass, detergents, food | Glass, chemicals | — |
| Phosphoric acid (technical, purified/food-grade) | Food, pharma, detergents, metal treatment | FMCG, food processors | 33,870 TPA food-grade project approved FY2015-16; new food-grade phosphoric acid plant at Dahej is a principal FY27–FY29 project (CARE) |
| Aluminium fluoride† | Fluxing agent | Aluminium smelters | Earlier disclosures; not re-verified in FY26 sources |
Pricing model
No product pricing disclosed. Caustic soda pricing is market-linked; GNAL–NALCO caustic sales are via competitive tenders; inter-company GACL–GNAL prices are based on production cost, demand, supply and market price (AR FY26 RPT annexure). CARE notes average caustic prices of US$452/MT in FY26 vs US$495/MT in FY25.
Financial Narrative
Basis of preparation
Published consolidated (equity method): GNAL accounted as JV; consolidated revenue equals standalone revenue. FY22–FY24 from Screener.in consolidated compilation; FY25–FY26 from AR FY26 Board's Report.
Rating-agency consolidated (full consolidation of GNAL): CARE's unaudited reconstruction (FY25–FY26 only).
- "EBITDA (consolidated basis)" follows Screener's convention, which embeds the share of JV loss in operating expenses; FY26 derived as standalone EBITDA excluding other income (₹405.21 Cr) less share of JV loss (₹23.25 Cr). This reconciles exactly to reported FY26 consolidated PBT of ₹20.72 Cr.
Income statement (published consolidated, INR Cr)
Gross profit: not publicly disclosed in comparable form (Indian Ind AS P&L presents expenses by nature; aggregator data lumps raw material, power and other costs).
FY22 growth computed from Screener FY21 revenue of ₹2,429 Cr. Tax for FY22–FY24 derived from Screener tax rates. FY26 dividend is recommended/declared for FY26 (paid after 30 Sep 2026).
Margins (published consolidated, %)
Revenue CAGR FY22–FY26: 3.8% (derived). Screener reports a 5-year sales CAGR of ~8% (FY20/21 base).
Standalone vs. rating-agency consolidated (INR Cr)
Note: CARE's "published" standalone-equivalent TOI (₹4,055 Cr FY25; ₹4,329 Cr FY26) differs from AR revenue from operations because of CARE's classification conventions.
Quarterly trajectory (INR Cr)
Sources: Univest/Kotak Neo (Q1FY26), multibagg/company release (Q2 sales revenue ₹1,063 Cr — may be a net-sales figure), Kotak Neo (Q3 PAT), FilingReader/NSE (Q4), ScanX/CARE (Q1FY27). Q1 FY27: CARE reports TOI ₹1,245 Cr and PBILDT margin 17.81% (vs 10.55% in Q1 FY26); ScanX reports standalone revenue of ₹1,224.84 Cr and standalone PBT of ~₹110 Cr — discrepancy between sources on standalone revenue noted.
Balance sheet (published consolidated, INR Cr)
Notes:
-
FY22–FY25 from Screener consolidated balance sheet. FY26 equity is derived (FY25 equity ₹5,669 Cr + FY26 total comprehensive loss ₹362.65 Cr – dividend paid ₹116.03 Cr). FY26 full balance sheet not accessed.
-
Long-term borrowings at 31 Mar 2026: ₹367.64 Cr (company's "not a Large Corporate" disclosure, 24 Apr 2026). CARE published consolidated gearing of 0.11x at 31 Mar 2026 implies total debt of roughly ₹570 Cr (derived), and net debt of roughly ₹400 Cr.
-
Goodwill & intangibles: not material / not separately disclosed in sources reviewed.
-
Working capital: Screener working-capital days of 4 (FY22), 5 (FY23), -1 (FY24), -3 (FY25) — effectively zero/negative net working capital.
Cash flow (published consolidated, INR Cr)
Sources: Screener/Motilal Oswal (CFO, CFI, CFF, FCF); capex derived as CFO – FCF; dividends paid FY22–FY24 derived as prior-year DPS × shares; FY25–FY26 from AR FY26. FY26 cash flow statement not accessed.
Ratios
ROE/ROA derived on average equity/assets; ROCE and working-capital days from Screener; FY26 D/E from CARE (published consolidated); FY26 CCC is CARE's "operating cycle". CARE's own published-basis interest coverage: 7.78x (FY25), 7.95x (FY26). ROIC not separately computable from available data; ROCE used as proxy. Current ratio: not publicly disclosed in the sources reviewed.
Commentary on trends, inflections and drivers
FY22–FY23 (cycle peak). Revenue rose 55% in FY22 and another 20% in FY23 to a record ₹4,516 Cr as global caustic prices spiked in the post-COVID energy shock. EBITDA (excluding other income) approached ₹1,000 Cr in both years. However, FY23 already showed margin compression (26% to 21%) and a sharp step-up in depreciation (₹198 Cr to ₹276 Cr) as the Dahej expansion and new derivative plants capitalised (CWIP fell from ₹1,787 Cr to ₹544 Cr while net block jumped by ~₹1,550 Cr).
FY24 (collapse). Revenue fell 16% and EBITDA collapsed to ₹32 Cr (0.8% margin). Three effects compounded: (i) caustic soda prices normalised as domestic capacity additions created oversupply; (ii) chlorine realisations turned deeply negative; and (iii) the newly capitalised asset base carried depreciation of ₹377 Cr and interest of ₹45 Cr regardless of utilisation. Operating cash flow fell to ₹67 Cr, yet the company paid a record ₹173 Cr in dividends (FY23's ₹23.55/share), funded from the balance sheet.
FY25 (stabilisation). Revenue recovered 7% to ₹4,073 Cr and standalone EBITDA (incl. OI) reached ₹452.56 Cr, but GNAL's ₹135 Cr loss (₹80.94 Cr share to GACL) kept consolidated PAT negative (₹-65 Cr). OCI losses of ₹239 Cr (fair value of equity investments) eroded book value.
FY26 (near break-even). Revenue grew another 7% to ₹4,358 Cr; standalone EBITDA rose 15.3% to ₹521.83 Cr, helped by power-cost relief (₹7.90/unit vs ₹8.42/unit) and higher other income (+26.6%). GNAL's loss narrowed to ₹39 Cr, so consolidated PAT was ₹-2.41 Cr. CARE nonetheless judged the recovery well below its expectations (it had expected 13–15% standalone PBILDT margins vs 8.74% delivered), citing moderate caustic prices (US$452/MT), negative chlorine realisations, weaker downstream offtake and slow chlorotoluene ramp-up. A further ₹360 Cr OCI loss reduced equity again.
Q1 FY27 (inflection). Record revenue (₹1,245 Cr) and a 17.81% PBILDT margin on a sudden uptick in caustic prices; consolidated PAT of ₹54.98 Cr already exceeds the entire FY22–FY26 cumulative consolidated profit since FY24. GNAL also posted an 18.63% PBILDT margin. Sustainability is the key debate.
Balance-sheet quality. Leverage is low (D/E ~0.1x published; ~0.38x on CARE's full-consolidation basis including GNAL debt and CCD backstop). The more significant balance-sheet risk is not debt but the volatility of mark-to-market equity investments and contingent support obligations to GNAL.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 3,759 | 4,516 | 3,807 | 4,072.91 | 4,358.07 |
Revenue growth YoY (%) | 54.8 | 20.1 | -15.7 | 7.0 | 7.0 |
EBITDA excl other income, JV share embedded (INR Cr) | 984 | 949 | 32 | 279 | 382 |
Other income (INR Cr) | 46 | 42 | 90 | 92.14 | 116.62 |
Depreciation & amortisation (INR Cr) | 198 | 276 | 377 | 392.30 | 414.48 |
Operating income EBIT incl other income (INR Cr) | 832 | 715 | -255 | -21 | 84 |
Finance cost (INR Cr) | 6 | 19 | 45 | 50.54 | 63.38 |
Profit before tax (INR Cr) | 826 | 695 | -300 | -71.22 | 20.72 |
Tax expense (INR Cr) | 266 | 285 | -63 | -6.10 | 23.13 |
Net profit (INR Cr) | 560 | 410 | -237 | -65.12 | -2.41 |
EPS basic (INR) | 76.22 | 55.78 | -32.25 | -8.87 | -0.33 |
EPS diluted (INR) | 76.22 | 55.78 | -32.25 | -8.87 | -0.33 |
Dividend per share (INR) | 10.00 | 23.55 | 13.85 | 15.80 | 17.70 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin excl OI (%) | 26.2 | 21.0 | 0.8 | 6.9 | 8.8 |
EBIT margin (%) | 22.1 | 15.8 | -6.7 | -0.5 | 1.9 |
PBT margin (%) | 22.0 | 15.4 | -7.9 | -1.7 | 0.5 |
Net margin (%) | 14.9 | 9.1 | -6.2 | -1.6 | -0.1 |
Income Statement and Margin Analysis (%) (FY2025–FY2026)
| Metric | FY2025 | FY2026 |
|---|---|---|
Standalone revenue from operations (INR Cr) | 4,072.91 | 4,358.07 |
Standalone EBITDA incl OI (INR Cr) | 452.56 | 521.83 |
Standalone EBITDA excl OI (INR Cr) | 360.42 | 405.21 |
Standalone EBITDA margin excl OI (%) | 8.8 | 9.3 |
Standalone PAT (INR Cr) | 15.82 | 20.84 |
Standalone EPS (INR) | 2.15 | 2.84 |
Standalone other comprehensive income (INR Cr) | -239.09 | -360.28 |
CARE full-consolidated TOI (INR Cr) | 4,849 | 5,091 |
CARE full-consolidated PBILDT (INR Cr) | 451 | 546 |
CARE full-consolidated PBILDT margin (%) | 9.31 | 10.72 |
CARE full-consolidated PAT (INR Cr) | -111 | 2 |
CARE full-consolidated interest coverage (x) | 2.42 | 3.56 |
CARE full-consolidated total debt to PBILDT (x) | 4.80 | 3.74 |
CARE full-consolidated overall gearing (x) | 0.37 | 0.38 |
Income Statement
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations, consolidated (INR Cr) | 1,105.12 | 1,063 | — | 1,125.31 | 1,244.91 |
Consolidated PAT (INR Cr) | -13.78 | 16.34 | -19.95 | 14.98 | 54.98 |
Standalone PAT (INR Cr) | 7.79 | — | — | 7.93 | 53.40 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 7,977 | 8,335 | 8,023 | 7,987 | — |
Net fixed assets (INR Cr) | 2,702 | 4,250 | 4,617 | 4,584 | — |
Capital work in progress (INR Cr) | 1,787 | 544 | 95 | 79 | — |
Investments (INR Cr) | 2,110 | 1,831 | 2,093 | 1,976 | — |
Total equity (INR Cr) | 5,899 | 6,139 | 6,075 | 5,669 | 5,190 |
Total borrowings (INR Cr) | 594 | 597 | 544 | 561 | — |
Free cash & equivalents (INR Cr) | — | — | — | 138 | 168 |
Net debt (INR Cr) | — | — | — | 423 | — |
Other liabilities (INR Cr) | 1,484 | 1,599 | 1,404 | 1,756 | — |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash flow from operations (INR Cr) | 735 | 960 | 67 | 381 | — |
Cash flow from investing (INR Cr) | -805 | -661 | -90 | -264 | — |
Cash flow from financing (INR Cr) | 12 | -140 | -277 | -145 | — |
Capex derived (INR Cr) | 908 | 683 | 231 | 322 | — |
Free cash flow (INR Cr) | -173 | 277 | -164 | 59 | — |
Dividends paid (INR Cr) | 59 | 73 | 173 | 101.71 | 116.03 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 9.9 | 6.8 | -3.9 | -1.1 | 0.0 |
ROA (%) | 7.4 | 5.0 | -2.9 | -0.8 | — |
ROCE (%) | 13 | 11 | -4 | 0 | — |
Debt to equity (x) | 0.10 | 0.10 | 0.09 | 0.10 | 0.11 |
EBITDA interest coverage (x) | 164 | 50 | 0.7 | 5.5 | 6.0 |
Net debt to EBITDA (x) | — | — | — | 1.5 | 1.1 |
Asset turnover (x) | 0.50 | 0.55 | 0.47 | 0.51 | — |
Cash conversion cycle (days) | 29 | 15 | 25 | 19 | 26 |
Debtor days | 29 | 23 | 17 | 24 | — |
Inventory days | 101 | 111 | 93 | 110 | — |
Payable days | 101 | 119 | 86 | 115 | — |
Revenue by Region and Revenue by Region (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations (INR Cr) | 3,807 | 4,072.91 | 4,358.07 |
Export revenue (INR Cr) | — | — | 920 |
Domestic revenue derived (INR Cr) | — | — | 3,438 |
Export share of revenue (%) | — | — | 21.1 |
Capital Markets
| Measure | Value | Source / date |
|---|---|---|
Last verified price | ₹640.30 | NSE, 18 Sep 2026 (ex-dividend date) |
52-week high / low | ₹815.00 / ₹409.15 | IIFL, Aug 2026 |
6-month return | +38.6% | Anand Rathi, to 18 Sep 2026 |
1-year return | +13.4% | Anand Rathi, to 18 Sep 2026 |
3-year price CAGR | ~5% | Screener (as of ~Apr 2026; dated) |
5-year price CAGR | ~14% | Screener (as of ~Apr 2026; dated) |
10-year price CAGR | ~16% | Screener (as of ~Apr 2026; dated) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | ~₹4,702 Cr | 7.344 Cr shares |
TTM P/E (consolidated) | ~71x | TTM PAT ₹66.35 Cr (Q2 FY26–Q1 FY27) |
P/B | ~0.91x (Screener-basis equity ~₹5,190 Cr) / ~1.15x (AR BVPS ₹556.82) | Two book-value conventions |
EV | ~₹5,100 Cr | Mkt cap + ~₹570 Cr debt – ₹168 Cr cash (derived) |
EV/EBITDA FY26 | ~13.4x (consolidated basis ₹382 Cr) / ~9.8x (standalone incl. OI ₹522 Cr) | Derived |
EV/Sales FY26 | ~1.17x | Derived |
Dividend yield | ~2.8% | ₹17.70 / ₹640.30 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 10.00 | 23.55 | 13.85 | 15.80 | 17.70 |
Dividend payout on consolidated profit (%) | 13 | 42 | -43 | -178 | -5,400 |
Capital Instruments
| Instrument | Amount (INR Cr) | Rating | History |
|---|---|---|---|
Long-term bank facilities (term loan ₹242.63 Cr maturing 17 Mar 2028; cash credit ₹130 Cr) | 372.63 | CARE AA-; Stable (3 Aug 2026) | AA+ (Jun & Sep 2023) → AA (13 Feb 2024; reaffirmed Aug 2024, Aug 2025) → AA- (Aug 2026) |
Short-term BG/LC | 339.50 | CARE A1+ | Reaffirmed |
Commercial paper | 100.00 | CARE A1+ | Nil outstanding at 10 Jul 2026 |
Analyst Conclusions
Management guidance
No numerical guidance. Management messaging (AR FY26, Q1 FY27) emphasises cost reduction, renewable substitution and value-added products, and points to Q1 FY27 as evidence of improvement. CARE expects consolidated operating profitability and debt coverage to improve in FY27, but below its earlier expectations.
Consensus expectations
Not available (no consensus coverage identified).
Bull case
-
Operating leverage is large: Q1 FY27 PBILDT margin of 17.81% vs 10.55% a year earlier turned a loss into ₹55 Cr quarterly PAT; with ~₹414 Cr of annual depreciation already absorbed, each percentage point of margin on ~₹4,800 Cr annualised revenue adds ~₹48 Cr EBITDA.
-
Structural cost decline: power is ~30–34% of TOI; moving renewables from ~35% to ~60% via already-contracted SPVs could durably lower unit power cost below FY26's ₹7.90.
-
Asset backing and yield: the stock trades near or below book (0.9–1.15x depending on convention), yields ~2.8%, carries low published leverage, and has a promoter group buying in the open market.
Bear case
-
Cyclical peak risk: Q1 FY27 was driven by a sudden caustic-price uptick; with domestic capacity ~6.7 Mtpa and up to ~2 Mt more in the pipeline (Adani, Reliance), FY27 margins may revert to the 8–10% range of FY25–FY26.
-
Chlorine remains a liability: negative realisations of ~₹7,000–8,000/MT persist and GACL lacks a PVC/EDC sink; derivative ramp-ups (chlorotoluene) have underdelivered.
-
Capital allocation and credit drift: a ₹1,300–1,400 Cr, 60–70% debt-funded capex programme follows a capex wave that drove ROE to ~0%; CARE already downgraded to AA-, and GNAL support obligations and OCI volatility continue to erode book value.
Catalysts and monitorables (next 12 months)
-
Q2 FY27 results (expected early-to-mid November 2026): sustainability of the Q1 margin.
-
Caustic soda price trend (domestic and SE Asia CFR) and chlorine realisations.
-
GNAL quarterly profitability and any further GACL financial support.
-
Commissioning of HCl unit #1, progress on high-purity H2O2 kick-off, phosphoric acid plant award.
-
Start of power flow from Aditya Birla (62.7 MW) and CleanMax (75.9 MW) SPVs; reported power cost per unit.
-
Financing of the capex programme; CARE's next review (Aug 2027) and any outlook change.
-
Promoter group buying; any GoG restructuring of state chemical PSUs.
-
Publication of "Vision 2047" details.
Analyst verdict
GACL is a well-capitalised, state-sponsored chlor-alkali franchise that has spent three years paying for an investment wave which arrived just as the Indian caustic soda market tipped into oversupply. The numbers tell the story plainly: consolidated EBITDA fell from roughly ₹950–985 Cr in FY22–FY23 to ₹32 Cr in FY24, before recovering only to ~₹380 Cr by FY26, while depreciation doubled to ₹414 Cr. Return on equity has averaged around 1% for three years, and the rating agency has cut the company two notches since 2023.
Against that, the balance sheet is unusually robust for a cyclical, the promoter is accumulating shares, and management has chosen the right levers: cheaper power through renewable SPVs, captive chlorine sinks, and a modest, sensible push into high-purity chemicals. The first quarter of FY27 demonstrated how quickly earnings respond when ECU realisations firm, with GNAL also turning operationally profitable.
The core judgment is whether Q1 FY27 is a turn or a blip. Our assessment is that the cost-side improvements (power, hydrogen monetisation, HCl capacity) are structural and will lift through-cycle margins by a few points, but the revenue-side upswing is cyclical and exposed to new vinyl-integrated capacity from very large competitors. On that basis, GACL screens as a value-oriented, dividend-supported cyclical recovery rather than a compounder. At roughly book value and ~10–13x FY26 EV/EBITDA, the valuation already discounts a partial normalisation; upside requires FY27 consolidated EBITDA margins sustainably above 12% (the CARE downgrade threshold) and visible GNAL profitability. Investors should track quarterly chlorine realisations and power cost per unit more closely than headline revenue. Absent formal guidance and sell-side coverage, information asymmetry is high, and position sizing should reflect that.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Appointed / tenure | Background (as disclosed) |
|---|---|---|---|---|
Dr. Hasmukh Adhia, IAS (Retd.) | Chairman | Non-executive, nominee/non-independent | — | — |
Smt. Avantika Singh (Aulakh), IAS | Managing Director | Executive (KMP) | MD since 3 Feb 2025 | Also MD of Gujarat Gas, GSPC and GSPC LNG, JMD of Gujarat State Petronet; Chairperson of GNAL; previously Vice-Chairman & CEO, Gujarat Maritime Board; CEO, Gujarat Infrastructure Development Board |
Dr. T. Natarajan, IAS | Director | Non-executive (GoG nominee) | Since 11 Sep 2024; retires by rotation, re-appointment at 2026 AGM | IAS 1996 batch; Additional Chief Secretary, Finance, Govt of Gujarat; ex-Senior Advisor to India's Executive Director at IMF; ex-Additional Secretary, Defence Production; BE (Guindy), MBA (Bharathidasan), Masters (Duke). Born 5 May 1971 (age 55) |
Shri Bimal Julka, IAS (Retd.) | Independent Director | Independent | — | Retired IAS officer |
Shri Nitin Shukla | Independent Director | Independent | Chair of Risk Management-cum-Safety Committee since 3 Feb 2024 | — |
Smt. Shridevi Shukla | Independent Director | Independent | — | — |
Dr. Chinmay Ghoroi | Independent Director | Independent | — | Also a director of GNAL |
Shri Sanjay Joshi | Independent Director | Independent | From 1 Jan 2026 (5-year term) | Global engineering leadership across India, Oman, Abu Dhabi, UK; ID at Ion Exchange (India); non-executive director at SLB Capturi India |
Board of Directors — Smt. Avantika Singh, IAS
| Name | Title | Since |
|---|---|---|
Smt. Avantika Singh, IAS | Managing Director | 3 Feb 2025 |
Shri Shailesh Damani | Chief Financial Officer | 8 Aug 2024 |
Shri Sanjay S. Bhatt | Company Secretary & Executive Director (Legal, CC & CSR) | KMP since 14 May 2014; nominee director on Aditya Birla Renewables SPV 4 since 5 Apr 2025 |
Shri G. S. Paliwal | Executive Director (Commercial); director on GNAL board | — |
Shri Dineshkumar Hingrajia | GM (Energy); nominee director, Clean Max Sphere Energy | From 24 Nov 2025 |
Shri Pankaj Pujara | Advisor to MD | Relieved 31 Mar 2026 |
Board & Management Changes
| Date | Change |
|---|---|
8 Aug 2024 | Shailesh Damani appointed CFO |
11 Sep 2024 | Dr. T. Natarajan, IAS appointed director |
3 Feb 2025 | Avantika Singh, IAS appointed MD (succeeding Swaroop P., IAS) |
16 May 2025 | S. J. Haider, IAS appointed director (shareholders approved by postal ballot 5 Jul 2025) |
31 Dec 2025 | Rajiv Lochan Jain completes tenure as ID; S. J. Haider resigns |
1 Jan 2026 | Sanjay Joshi appointed Independent Director (approved by postal ballot 21 Mar 2026) |
31 Mar 2026 | Pankaj Pujara relieved as Advisor to MD |
Major Shareholders
| Holder category | Stake (latest) | Source/date |
|---|---|---|
Promoter & promoter group (GoG undertakings) | 47.28% | CARE / exchange filings, 30 Jun 2026 |
— of which Gujarat State Investments Ltd | 20.87% | CARE, Jun 2026 |
Foreign institutional investors | ~3.3% (sources range 1.91%–3.30%) | Dhan/Share.market, Jun–Jul 2026 |
Domestic institutional investors | ~1.6%–3.0% (sources conflict) | Share.market / Anand Rathi, Jun 2026 |
Public / retail and others | ~46.4% | Share.market, Jul 2026 |
Competitive Landscape
Competitors by Segment
| Business line | Named competitors | Notes |
|---|---|---|
Caustic soda / chlor-alkali | Grasim Industries (Aditya Birla Chemicals) — market leader; DCM Shriram (Jhagadia, Bharuch: India's largest single-site caustic facility at 2,225 TPD after an 850 TPD expansion); Tata Chemicals; Epigral (formerly Meghmani Finechem); Kutch Chemical Industries; TGV SRAAC; Chemplast Sanmar; Lords Chloro Alkali; Chemfab Alkalis (65,700 TPA); Nirma | GACL ranked third by capacity (CARE) |
Prospective entrants | Adani (Mundra 2,200 TPD chlor-alkali plant under execution tied to 1 Mtpa PVC); Reliance (planned) | Nearly 2 Mt of new capacity potentially in pipeline (Price Watch, 2026) |
Chloromethanes | SRF, Gujarat Fluorochemicals, Chemplast Sanmar | Captive fluorochemical integration advantages for peers |
Hydrogen peroxide | National Peroxide; Aditya Birla group; imports (especially for electronic grade) | GACL historically among largest domestic producers |
Phosphoric acid (purified/food) | Domestic fertiliser-linked producers and imports | — |
Benzyl chloride/alcohol/benzaldehyde | Domestic specialty producers and Chinese imports | — |
Peer Comparison FY2026
| Metric | GACL | DCM Shriram (Chloro-Vinyl) |
|---|---|---|
Revenue | ₹4,358 Cr (standalone); ₹5,091 Cr incl. GNAL (CARE) | — |
Revenue growth | +7.0% | — |
EBITDA margin | 9.3% standalone excl OI; 10.7% CARE consolidated | — |
Caustic capacity | ~3,000 TPD (group) | Jhagadia 2,225 TPD (single site) |



